ALPHA-1062

About Alpha Cognition

Alpha Cognition is a clinical-stage biotech with a mission to develop superior symptomatic treatments for neurodegenerative disorders, starting with Alzheimer's disease. Its core achievement is the development of ALPHA-1062, a proprietary prodrug designed to deliver the efficacy of galantamine while significantly reducing its dose-limiting side effects, potentially improving patient quality of life and adherence. The company's strategy is to advance ALPHA-1062 through clinical trials as a best-in-class acetylcholinesterase inhibitor and leverage its prodrug platform to create other optimized neurological therapeutics. Operating as a lean, publicly-traded entity, Alpha Cognition aims to create value by addressing clear unmet needs within established treatment paradigms.

Therapeutic Areas

Other Mild-to-Moderate Alzheimer's Disease Drugs